Loading stock data…
STIM
$1.24-0.04 (-3.12%)
After Hours$1.24+0.00 (+0.02%)· Last close Jun 9
Neuronetics, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Neuronetics, Inc. in the Healthcare sector is trading at $1.24. Wall Street consensus targets $4.33 (3 analysts), implying a +249.5% move over the next 12 months. The stock is currently near its 52-week low of $0.80, remaining 35.8% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +249.5% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$1.24
Potential Downside
0%
Whystock Fair Value$1.24
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company provides NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatme...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-279.78%
Volume
Today's trading volume
1.27M
Recent News
Neuronetics Q1 Earnings Call Highlights
Neuronetics (NASDAQ:STIM) reported first-quarter 2026 results that management said were largely in line with expectations, as the company balanced growth in its Greenbrook clinic business with a slight decline in overall NeuroStar revenue. President and CEO Dan Reuvers, who led his first earnings ca
Neuronetics, Inc. Q1 2026 Earnings Call Summary
Moby summary of Neuronetics, Inc.'s Q1 2026 earnings call
Neuronetics (STIM) Q1 2026 Earnings Transcript
Mark Klausner: Good morning, and thank you for joining us for the Neuronetics First Quarter 2026 Conference Call. Joining me on today's call is Neuronetics' President and Chief Executive Officer, Dan Reuvers. Before we begin, I would like to caution listeners that certain information discussed by management during this conference call will include forward-looking statements covered under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements related to our business, strategy, financial and revenue guidance and other operational issues and metrics.
Neuronetics (STIM) Reports Q1 Loss, Tops Revenue Estimates
Neuronetics (STIM) delivered earnings and revenue surprises of +5.88% and +0.60%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
How The Neuronetics (STIM) Investment Story Is Evolving With A Reset Price Target
The recent update on Neuronetics centers on a $4 reduction in the price target, with the fair value estimate held at $4.33. Analysts describe this move as a recalibration to refreshed assumptions rather than a change in the core thesis, reflecting a more measured stance on risk and execution. As you read on, you will see how this evolving narrative around the price target can influence the way you interpret the stock today. Analyst Price Targets don't always capture the full story. Head over...